Study Summary
This trial will test an allogeneic cryopreserved NK cell therapy derived from donor peripheral blood, in combination with rituximab, for patients with relapsed or refractory B Cell non-Hodgkin lymphoma.
- Non-Hodgkin Lymphoma
- Non-Hodgkin's Lymphoma
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 0 Secondary · Reporting Duration: up to 1 year
Trial Safety
Trial Design
0 Treatment Group
99 Total Participants · 0 Treatment Group
Primary Treatment: Treatment · No Placebo Group · Phase 1 & 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 9 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
How many participants are engaged in this trial?
"To adequately conduct this research, Gamida Cell Ltd needs 99 participants who comply with the selection criteria. The trial will be run at Loyola University, Cardinal Bernardin Cancer Center in Maywood, Illinois and Dana-Farber/Mass General Brigham Cancer Care, Inc. in Boston, Massachusetts respectively." - Anonymous Online Contributor
How many healthcare facilities are participating in this trial?
"At present, there are 4 trial sites hosting this medical study. Two of the locations are in Maywood and Boston while Detroit is another option. Additionally, there exist other centres nearby to reduce travelling if you choose to participate." - Anonymous Online Contributor
Is enrollment for this trial still open to participants?
"As of the August 15th update, this clinical trial is still actively looking for participants. The original post was made to clinicaltrials.gov on July 5th 2022." - Anonymous Online Contributor